Xintela AB (publ)

OM:XINT Stock Report

Market Cap: SEK 196.8m

Xintela Valuation

Is XINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XINT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XINT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XINT?

Key metric: As XINT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for XINT. This is calculated by dividing XINT's market cap by their current book value.
What is XINT's PB Ratio?
PB Ratio-7.7x
Book-SEK 25.67m
Market CapSEK 196.79m

Price to Book Ratio vs Peers

How does XINT's PB Ratio compare to its peers?

The above table shows the PB ratio for XINT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2x
COEGIN Coegin Pharma
3.5x16.4%SEK 75.8m
VIVE Vivesto
0.9x21.8%SEK 150.1m
ELIC Elicera Therapeutics
2.4x-15.2%SEK 60.9m
XBRANE Xbrane Biopharma
1.1x130.2%SEK 294.6m
XINT Xintela
n/an/aSEK 196.8m

Price-To-Book vs Peers: XINT has negative equity and a Price-To-Book Ratio (-7.7x) compared to the peer average (2x).

Price to Book Ratio vs Industry

How does XINT's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
COMBI CombiGene
0.6xn/aUS$4.59m
EXPRS2 ExpreS2ion Biotech Holding
0.6x-11.9%US$3.66m
SCOL Scandion Oncology
0.5x69.7%US$1.52m
DIABIO Diagonal Bio
0.5xn/aUS$1.23m
XINT is unprofitableIndustry Avg. 2.4xNo. of Companies11PB02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: XINT has negative equity and a Price-To-Book Ratio (-7.7x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is XINT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XINT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-7.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XINT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

7D

5.0%

1Y

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

7D

-2.7%

1Y

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-8.1%

1Y

n/a